Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.

Publication ,  Journal Article
Maze, D; Arcasoy, MO; Henrie, R; Cerquozzi, S; Kamble, R; Al-Hadidi, S; Yacoub, A; Singh, AK; Elsawy, M; Sirhan, S; Smith, E; Marcoux, C ...
Published in: Bone Marrow Transplant
February 2024

Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF) and is recommended for patients with higher risk disease. However, there is a risk of early mortality, and optimal timing is unknown. JAK inhibitor (JAKi) therapy may offer durable improvement in symptoms, splenomegaly and quality of life. The aim of this multicentre, retrospective observational study was to compare outcomes of patients aged 70 years or below with MF in chronic phase who received upfront JAKi therapy vs. upfront HCT in dynamic international prognostic scoring system (DIPSS)-stratified categories. For the whole study cohort, median overall survival (OS) was longer for patients who received a JAKi vs. upfront HCT, 69 (95% CI 57-89) vs. 42 (95% CI 20-not reached, NR) months, respectively (p = 0.01). In patients with intermediate-2 and high-risk disease, median OS was 55 (95% CI 36-73) months with JAKi vs. 36 (95% CI 20-NR) months for HCT (p = 0.27). An upfront HCT strategy was associated with early mortality and difference in median OS was not observed in any risk group by 5 years of follow-up. Within the limitations of a retrospective observational study, we did not observe any benefit of a universal upfront HCT approach for higher-risk MF.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Bone Marrow Transplant

DOI

EISSN

1476-5365

Publication Date

February 2024

Volume

59

Issue

2

Start / End Page

196 / 202

Location

England

Related Subject Headings

  • Transplantation, Homologous
  • Retrospective Studies
  • Quality of Life
  • Primary Myelofibrosis
  • North America
  • Janus Kinase Inhibitors
  • Immunology
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Maze, D., Arcasoy, M. O., Henrie, R., Cerquozzi, S., Kamble, R., Al-Hadidi, S., … Gupta, V. (2024). Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study. Bone Marrow Transplant, 59(2), 196–202. https://doi.org/10.1038/s41409-023-02146-6
Maze, Dawn, Murat O. Arcasoy, Ryan Henrie, Sonia Cerquozzi, Rammurti Kamble, Samer Al-Hadidi, Abdulraheem Yacoub, et al. “Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.Bone Marrow Transplant 59, no. 2 (February 2024): 196–202. https://doi.org/10.1038/s41409-023-02146-6.
Maze D, Arcasoy MO, Henrie R, Cerquozzi S, Kamble R, Al-Hadidi S, et al. Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study. Bone Marrow Transplant. 2024 Feb;59(2):196–202.
Maze, Dawn, et al. “Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.Bone Marrow Transplant, vol. 59, no. 2, Feb. 2024, pp. 196–202. Pubmed, doi:10.1038/s41409-023-02146-6.
Maze D, Arcasoy MO, Henrie R, Cerquozzi S, Kamble R, Al-Hadidi S, Yacoub A, Singh AK, Elsawy M, Sirhan S, Smith E, Marcoux C, Viswabandya A, Daly A, Sibai H, McNamara C, Shi Y, Xu W, Lajkosz K, Foltz L, Gupta V. Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study. Bone Marrow Transplant. 2024 Feb;59(2):196–202.

Published In

Bone Marrow Transplant

DOI

EISSN

1476-5365

Publication Date

February 2024

Volume

59

Issue

2

Start / End Page

196 / 202

Location

England

Related Subject Headings

  • Transplantation, Homologous
  • Retrospective Studies
  • Quality of Life
  • Primary Myelofibrosis
  • North America
  • Janus Kinase Inhibitors
  • Immunology
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • 3211 Oncology and carcinogenesis